GlassScriptPhysician profile
Simon Grinshteyn
NPI 1841589173
$1,725.94
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.68 · 2020: $22.22 · 2021: $605 · 2022: $910 · 2023: $48.22 · 2024: $83.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $132.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $214.30 | 2021-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $130.55 | 2021-2022 | |
| Novo Nordisk INC | $119.56 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.76 | 2021-2022 | |
| Antares Pharma, INC. | $117.84 | 2021-2022 | |
| Philips North America LLC | $103.04 | 2023-2024 | (Cm9) Amb Mon & Diag Und, (5091) Amb Mon & Diag Und |
| Horizon Therapeutics Plc | $78.40 | 2021-2022 | |
| Abbvie INC. | $77.77 | 2022 | |
| Amgen INC. | $67.63 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $63.43 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $56.19 | 2021 | |
| Organogenesis INC. | $56.05 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $49.42 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.48 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.91 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $39.17 | 2021-2022 | |
| Glaxosmithkline, LLC. | $37.26 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.72 | 2022 | |
| Dexcom, INC. | $28.89 | 2021 | |
| Lundbeck LLC | $28.10 | 2022 | |
| Allergan, INC. | $27.99 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $26.75 | 2021 | |
| Sunovion Pharmaceuticals INC. | $24.28 | 2021 | |
| Insulet Corporation | $20.59 | 2022 | |
| Kci USA, INC. | $19.84 | 2022 | |
| Smith+Nephew, INC. | $17.15 | 2022 | |
| Integra Lifesciences Corporation | $15.74 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.50 | 2023 | Quviviq |
| Nestle Healthcare Nutrition INC. | $14.38 | 2022 | |
| Pfizer INC. | $12.95 | 2019 | |
| Medtronic, INC. | $12.18 | 2021 | |
| Phadia US INC. | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Grinshteyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.